Recent progress in treatment of pulmonary arterial hypertension due to congenital heart disease

Netherlands Heart Journal

Volumn 19, Issue 12, 2011, Pages 495-497

  Schuuring, M J ^a,b   van Riel, A C M J ^a,b   Bouma, B J ^a   Mulder, B J M ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PROSTACYCLIN; SILDENAFIL;

CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EDITORIAL; EISENMENGER COMPLEX; FONTAN PROCEDURE; HEART SURGERY; HUMAN; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PATIENT SELECTION; PULMONARY HYPERTENSION; TREATMENT INDICATION;

EID: 83155165518     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0220-3     Document Type: Editorial

References (13)

1. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120 (2):198-204.
2. Baumgartner H, Bonhoeffer P, De Groot NMS, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23): 2915-29.
3. Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2011.
4. Schuuring M, Bouma B, Cordina R, et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol. 2011;In press.
5. Schuuring M, Boekholdt S, Windhausen A, et al. Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. Submitted. 2011.
6. Joffs C, Walker CA, Hendrick JW, et al. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2001;122 (2):365-370.
7. Palma G, Giordano R, Russolillo V, et al. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. Tex Heart Inst J. 2011;38(3):238-242.
8. Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123 (11):1185-1193.
9. Schölzel BE, Snijder RJ, Morshuis WJ, et al. Clinical worsening after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Neth Heart J. 2011.
10. Hoendermis ES. Pulmonary arterial hypertension: an update. Neth Heart J 2011;
11. Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary hypertension. Neth Heart J. 2011.
12. Dorfmüller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22(2):358-363.
13. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171-1177.